Company / Interest Expense
Sonoma Pharmaceuticals, Inc. Interest Expense History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
-$10.0K
FY2023
5-year range
-$10.0K / $4.0K
FY2019-FY2023
Trend
-350.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense changed -350% YoY in FY2023, a notable deviation from the 6-year average annual change of +123%.
Based on SEC 10-K filings.
-$10,000 in FY2023.
Improved from $16,000 to -$10,000 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Sonoma Pharmaceuticals, Inc.'s interest expense has declined for 4 consecutive years.
- In FY2023, interest expense decreased 350.0% year-over-year.
- Peak interest expense was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | - | - |
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$10.0K | -350.0% |
| FY2022 | $4.0K | -75.0% |
| FY2021 | $16.0K | -51.5% |
| FY2020 | $33.0K | -17.5% |
| FY2019 | $40.0K | +1233.3% |
| FY2018 | $3.0K | +0.0% |
| FY2017 | $3.0K | +0.0% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026